Funding
This work was supported by NIH grants (Grant Nos. U01210170 and R01CA176828 CA62924), Susan Wojcicki and Dennis Troper, a Stand Up to Cancer-Lustgarten Foundation Pancreatic Cancer Interception Translational Cancer Research grant (Grant No. SU2C-AACR-DT25-17). Stand Up to Cancer is a program of the Entertainment Industry Foundation. The SU2C research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
Michael Goggins is the Sol Goldman Professor of Pancreatic Cancer Research. A Fujimoto Medical System Scholarship to YA and the International Research Fund for Subsidy of Kyushu University School of Medicine Alumni.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ando, Y., Dbouk, M., Blackford, A.L. et al. ASO Visual Abstract: Using a CA19-9 Tumor Marker Gene Test to Assess Outcome After Pancreatic Cancer Surgery. Ann Surg Oncol 31, 2979–2980 (2024). https://doi.org/10.1245/s10434-024-15023-3
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-024-15023-3